Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

Mathias J Rummel,Christian Lerchenmüller,Manfred Hensel,Martin Goerner,Christian Buske,Holger Schulz,Burkhard Schmidt,Georgi Kojouharoff,Elisabeth Lange,Wolfgang Willenbacher,Jan Dürig,Erik Engel,Frank Kauff,Jürgen Barth,Alexander Christoph Burchardt,Axel Hinke,Jasmin Wupperfeld,Richard Greil

doi:10.1182/blood-2019-121909

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

Mathias J Rummel, Christian Lerchenmüller + Show 16 more

Open Access

https://doi.org/10.1182/blood-2019-121909

Copy DOI

Journal: Blood	Publication Date: Nov 13, 2019
Citations: 40

Affiliation: University of Giessen, Paracelsus Medical University, Society of Paediatric Oncology and Haematology, Universität Innsbruck, University Hospital Ulm, Essen University Hospital, University Medical Centre Mannheim, Evangelisches Krankenhaus Hamm, University Hospital Münster

#Advisory Committees #Research Funding + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

Full Text